COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of LY3556050 in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04156750
Recruitment Status : Completed
First Posted : November 7, 2019
Last Update Posted : August 19, 2020
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The main purpose of this study is to learn more about the safety of LY3556050 after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3556050 or placebo and will remain in the study for up to 31 days.

Condition or disease Intervention/treatment Phase
Healthy Drug: LY3556050 Drug: Placebo Drug: Iohexol Drug: Metformin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Part A - Parallel design. Part B - Open label design.
Masking: Double (Participant, Investigator)
Masking Description: Part A - Double-blind. Part B - Open label.
Primary Purpose: Basic Science
Official Title: Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study With LY3556050 in Healthy Subjects
Actual Study Start Date : November 20, 2019
Actual Primary Completion Date : August 3, 2020
Actual Study Completion Date : August 3, 2020

Arm Intervention/treatment
Experimental: LY3556050 (Part A)
LY3556050 administered orally.
Drug: LY3556050
Administered orally.

Placebo Comparator: Placebo (Part A)
Placebo administered orally.
Drug: Placebo
Administered orally.

Iohexol (Part B)
Iohexol given intravenously (IV). (Part B is optional.)
Drug: Iohexol
Administered IV.

Metformin (Part B)
Metformin given orally. (Part B is optional.)
Drug: Metformin
Administered orally.

Experimental: LY3556050+ Iohexol (Part B)
Iohexol given intravenously (IV) coadministered with oral doses of LY3556050. (Part B is optional.)
Drug: LY3556050
Administered orally.

Drug: Iohexol
Administered IV.

Experimental: LY3556050 + Metformin (Part B)
Metformin given orally coadministered with oral doses of LY3556050. (Part B is optional.)
Drug: LY3556050
Administered orally.

Drug: Metformin
Administered orally.

Primary Outcome Measures :
  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Final Follow-up (up to Week 9)] ]
    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Secondary Outcome Measures :
  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3556050 [ Time Frame: Baseline through Day 17 ]
    PK: Cmax of LY3556050

  2. PK: Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ) [ Time Frame: Baseline through Day 17 ]
    PK: AUCτ of LY3556050

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy males or females of nonchild bearing potential, as determined by medical history
  • Have safety laboratory results within normal references ranges
  • Weight at least 50 kilograms (kg)

Exclusion Criteria:

  • Have known allergies to LY3556050, iodine, metformin and related compounds
  • Abnormal electrocardiogram (ECG) or blood pressure at screening
  • Significant history of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or endocrine disorders
  • Show evidence of active renal disease with estimated glomerular filtration rate (GFR) <90 milliliters per minute per 1.73 meters squared

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04156750

Layout table for location information
United States, Texas
Dallas, Texas, United States, 75247
Sponsors and Collaborators
Eli Lilly and Company
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Layout table for additonal information
Responsible Party: Eli Lilly and Company Identifier: NCT04156750    
Other Study ID Numbers: 17612
J2P-MC-LXBA ( Other Identifier: Eli Lilly and Company )
First Posted: November 7, 2019    Key Record Dates
Last Update Posted: August 19, 2020
Last Verified: August 15, 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypoglycemic Agents
Physiological Effects of Drugs